GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Short Interest

Apollomics (Apollomics) Short Interest


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Apollomics's Short Interest

For the Biotechnology subindustry, Apollomics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Short Interest distribution charts can be found below:

* The bar in red indicates where Apollomics's Short Interest falls into.


Apollomics (Apollomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Short Interest
Comparable Companies
ATHA STTK ACXP CARA TLSA ORMP IMMX CCCC GTHX GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
APLM:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.